ProCR™

Modified Release: ProCR™ Technology

ProCR™ is a matrix tablet formulated with a combination
of three commercially available polymers.

  • Novel composition
  • Three commercially available polymers
  • Near linear release
  • Applicable to a wide range of doses and drug solubility
  • Patents filed in 4Q08
  • Flexible array of drug release profiles

Delayed-Extended Release

  • Coating applied to ProCR™ tablets can provide a delayed-extended release.
  • Customized profile achieved by changing coating porosity or thickness.

procr
ProCR™ Dissolution Profiles of Three Drug Candidates

Potential Benefits:

  • Improved Therapy
  • Decrease number of daily doses improves compliance
  • Decrease adverse effects due to better plasma concentration control
  • Customizable Release Profile: Burst, Extended, Delayed

procr

procr

ProCR™: Case Study Comparison to Procardia XL®

  • Procardia XL® (nifedipine) is very insoluble
  • Only match is an osmotic tablet (more expensive to manufacture)
  • Two AAIPharma formulations match innovator profile in-vitro
  • Osmotic performance without manufacturing complexity
  • PK study scheduled for August 2009 to confirm in-vivo correlation
Contact